Explore by Goal

Quick Explanation Copied

Author review — Rolf Müller (scientific strengths at a glance)

Rolf Müller is a well-established natural‑products / biosynthesis researcher with multiple high‑impact papers on microbial biosynthetic gene clusters (BGCs), polyketide synthases, and myxobacterial natural products; his recent work includes structure, BGC and ADME analysis of new sorangicin derivatives (neosorangicin A) highlighting strengths in integrated chemistry–genomics–pharmacology approaches ;

Representative prior work shows deep expertise in BGC/genome mining and myxobacterial natural products (e.g., complete Sorangium genome and antiSMASH/BGC tool use) and methods for BGC mining/annotation (antiSMASH) where Müller is a co-author .

Long Explanation

Author Review — Rolf Müller

Visual summary (graphs first, details second)

Evidence base — what the literature shows

Recent integrated natural-product study (2026): Neosorangicin A (neosorangicin A) paper presents isolation, full NMR/HRESIMS structure work, analysis of an nsr trans‑AT PKS BGC (~124 kb, 21 genes) and a careful ADME/pharmacology pipeline that reveals potent in vitro and intracellular RNAP inhibition but rapid plasma/wound-fluid instability that prevents in vivo efficacy — this demonstrates capability across chemistry, genomics and preclinical pharmacology
Genomic tools & BGC discovery: antiSMASH (coauthored by community that includes Müller) is foundational for BGC detection and appears in this author group’s toolkit; it underpins credible genome-to-metabolite links in the literature cited here
Myxobacterial genomics & natural-product expertise: Complete Sorangium cellulosum genome sequencing and follow-up analyses have been central to myxobacterial natural‑product discovery and are part of the evidence base connected to Müller’s field (Sorangium genome paper is a key foundation)
Mechanistic / evolutionary PKS insights: Müller appears on papers about polyketide synthase evolution and biosynthetic mechanisms (e.g., evolutionary implications of PKS) that show substantive domain-level enzymology expertise useful for biosynthetic interpretation

Assessment — strengths, limitations, and blindspots

Strengths: integrated chemistry–genomics approach (isolation + NMR + genome sequencing + BGC annotation + PK/ADME profiling) demonstrates methodological breadth; authorship on high‑impact tool/papers (antiSMASH, Sorangium genome, PKS evolution) indicates domain expertise and credible community impact .

Limitations & blindspots observed in the provided corpus:

Translational gap: the 2026 neosorangicin A study explicitly shows a major ADME liability (very short mouse plasma half‑life) that prevented in vivo efficacy despite potent in vitro activity — this is a documented translational blindspot (common in natural-product antibiotic discovery)
Model dependence: in vivo failure observed in a single SKH1 murine wound infection model — authors note it may be species/model specific and highlight missing cross-species PK data (a limitation for generalizing to human potential)
Reproducibility/transparency: some accession numbers (GenBank, nmrXiv) were pending at time of reporting — that reduces immediate reproducibility until raw data are fully deposited (authors stated deposit to follow)

Potential biases to watch: natural-product discovery fields suffer publication bias toward positive leads and selection bias in screened strains; the integrated pipeline shown mitigates some risks by including ADME early, but pay attention to small‑n in vivo experiments and single‑model conclusions.

Concrete, actionable recommendations for strengthening the author’s scientific impact

Standardize data deposition (immediate GenBank, nmrXiv, raw LC‑MS/TIMS files) so others can reanalyze BGC–metabolite links and ADME data; transparent raw data increases reproducibility and citation potential.
Focus on early cross‑species ADME profiling and ex vivo wound‑fluid stability assays to triage candidates before animal efficacy studies (the 2026 paper shows this would have predicted in vivo failure)
Integrate medicinal‑chemistry or formulation routes early (stabilizing modifications, prodrugs, topical vehicles) to rescue potent but labile natural products; co‑publishing such rational optimization increases translational value and citations.
When possible, publish larger‑n in vivo or multi‑model validation to reduce model‑specific interpretations; this will strengthen claims of translational relevance.

Selected citations supporting this review

Feedback:

Updated: March 10, 2026

BGPT Author Review

Scientific Quality

80%

Demonstrates deep domain expertise in natural-product chemistry, PKS biosynthesis and genome‑to‑metabolite workflows with multiple high‑impact contributions and strong methodological breadth; translational weakness shown by ADME instability in at least one recent lead limits immediate clinical impact but not scientific quality.

Communication Quality

80%

Papers show clear technical exposition across chemistry, genomics and pharmacology; data presentation is generally thorough although some raw-data accessions were pending in the recent paper, which reduces immediate reproducibility.

Author Novelty

80%

Work combines established genome-mining tools with new natural-product chemistry; studies often report novel metabolites or biosynthetic innovations (e.g., trans-AT PKS architecture and new sorangicin derivatives).

Scientific Rigor

80%

High methodological rigor (NMR, HRESIMS, genomic BGC annotation, enzyme/domain-level analyses, ADME profiling) with transparent reporting of negative in vivo outcomes, but reproducibility could improve with earlier/complete raw-data deposition.

Top Data Sources Export MCP

1. Isolation and structural elucidation of neosorangicin A (1) and its glucoside neosorangioside A (2) from Sorangium cellulosum Soce439, analysis of the nsr biosynthetic gene cluster, demonstration of stronger in vitro and intracellular activity than sorangicin A in several assays, but lack of in vivo efficacy in a murine wound infection model due to rapid degradation in plasma/wound exudate, highlighting early ADME liabilities in antibiotic development. [2026]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. Deleting HydA2 and HydBA in Acetobacterium woodii enables growth on carbon monoxide, and subsequent adaptation reveals HycB2-driven rerouting of electron flow to ferredoxin that enhances formate-driven biomass production and CO metabolism. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. Identification and functional characterization of the crocacin biosynthetic gene cluster in Chondromyces crocatus Cm c5, revealing an unusual hydrolytic release domain (CroK-C2) that releases crocacin B from the assembly line, supported by in vitro kinetics and heterologous production studies that illuminate NRPS/PKS domain versatility and potential for engineering. [2014]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

4. Systematic benchmarking reveals that constraining seed length to 7 base pairs with no GU in seeds, enforcing seed accessibility, and capping the maximal interaction length around 60 nt substantially improves sRNA target prediction accuracy and reduces runtime in IntaRNA, with SHAPE-based ShaKer data providing additional gains for target sequences. [2020]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. This study presents the total synthesis and biological evaluation of miuraenamides, cyclodepsipeptides with significant antitumor activity, achieved through a novel peptide modification approach. [2015]

8QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

Key Insight

High-quality natural-product discovery must pair potent in vitro mechanisms with early, cross-species pharmacokinetic profiling — a strong discovery pipeline is only translationally useful if ADME liabilities are identified and addressed early.

Keep Exploring

Which specific nsr tailoring enzymes (by gene ID) plausibly produce the labile moiety in neosorangicin A, and can their activity be tested in vitro?

Can formulation or prodrug strategies (liposomal topical delivery, ester prodrugs) extend neosorangicin A half-life in wound fluid without compromising bacterial uptake?

Analysis Wizard

Preparing a script to parse GenBank BGC sequences and produce a domain-by-domain comparison heatmap (nsr vs sor clusters) to prioritize tailoring enzymes linked to ADME-relevant modifications.

Hypothesis Graveyard

The in vivo failure of neosorangicin A is due to lack of antibacterial potency alone — falsified because the compound is potent in vitro and intracellularly but degraded rapidly in plasma/wound fluid (ADME explanation fits better).

BGC sequence similarity alone predicts in vivo efficacy — unlikely because small tailoring changes (glycosylation, side-chain truncations) produce large ADME differences that sequencing alone cannot predict.

Potential Experiments

Direct ex vivo wound‑fluid stability assay across mouse, rat and human surgical wound exudates with LC‑MS quantification to map species differences in degradation kinetics and identify responsible enzymes (esterases/proteases) to guide stabilization chemistry.

Structure‑activity PK rescue study: synthesize a small focused set (6–8) of neosorangicin analogs with modifications at predicted labile positions (e.g., oxidation-prone secondary alcohol → fluorinated or methylated analogues; glycoside site alterations) and evaluate plasma half-life, RNAP IC50, and intracellular potency to find analogs retaining activity and improved stability.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I emphasize empirical experimental evidence and biochemical/PK explanations; I may underweight non-DOI bibliometric sources due to citation-format constraints.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied